ORAL 25(OH)D3 ON PLASMA LEVELS OF 1,25(OH)2D3 BY PERITONEAL MACROPHAGES

口服 25(OH)D3 对腹膜巨噬细胞血浆 1,25(OH)2D3 水平的影响

• 批准号: 3882848
• 负责人: JAMES A. DELMEZ
• 金额: --
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3882848
• 关键词: 1,25 dihydroxycholecalciferol; 25 hydroxycholecalciferol; blood chemistry; continuous ambulatory peritoneal dialysis; drug administration routes; human subject; human therapy evaluation; kidney disorder chemotherapy; macrophage; parathyroid hormones; peritoneum; renal failure; vitamin biosynthesis; vitamin metabolism; vitamin therapy

Patients undergoing chronic ambulatory peritoneal dialysis received oral 25-(OH)D3. The effect of treatment on serum 25-OHD and 1,25(OH)2D3 and PTH 1,25(OH)2D3 is assessed.

接受慢性非卧床腹膜透析的患者接受口服 25-(OH)D3。 治疗对血清25-OHD和1,25(OH)2D3及PTH的影响 评估 1,25(OH)2D3。